Skip to main content
Smart Investors Daily
DB

NASDAQ · DBVT

DBV Technologies S.A.

Healthcare · Biotechnology

$11.79

Up+$0.03 (+0.26%)

Updated Sep 17, 2026, 10:21 AM

SID Score

2.9/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
464.56M
P/E ratio
-4.18
Dividend yield
0.00%
52-week range
$11.70 – $24.05
Volume
159.08K
Avg. volume
215.76K

Price performance

DBVT price history

1M range · 20 trading sessions · Daily adjusted prices

DBVT closed at $11.79 after 20 trading sessions, down 20.23% for the selected period.

Last close
$11.79
Period change
-20.23%
Period low
$11.76
Period high
$14.97
Daily close
View OHLC price history
DBVT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$12.20$12.21$11.75$11.79159.08K
Sep 15, 2026$12.20$12.2505$11.695$11.76175.07K
Sep 14, 2026$12.20$12.62$11.92$12.35269.58K
Sep 11, 2026$13.04$13.15$11.80$11.852.7M
Sep 10, 2026$13.51$13.51$12.93$12.97125.35K
Sep 9, 2026$13.24$13.63$13.24$13.4489.62K
Sep 8, 2026$13.40$13.465$13.14$13.27181.29K
Sep 4, 2026$13.42$13.58$13.30$13.4743.08K
Sep 3, 2026$13.90$13.90$13.44$13.70145.25K
Sep 2, 2026$13.69$13.97$13.40$13.61185.68K
Sep 1, 2026$13.58$13.72$13.09$13.42250.61K
Aug 31, 2026$13.75$13.86$13.57$13.82179.19K
Aug 28, 2026$14.38$14.38$13.45$13.54146.15K
Aug 27, 2026$14.56$14.58$14.30$14.41131.02K
Aug 26, 2026$14.67$14.71$14.14$14.52242.52K
Aug 25, 2026$14.88$15.13$14.73$14.97154.94K
Aug 24, 2026$14.28$14.36$13.98$14.14122.74K
Aug 21, 2026$14.43$14.75$14.33$14.55124.58K
Aug 20, 2026$14.42$14.7099$14.18$14.24119.34K
Aug 19, 2026$15.09$15.10$14.47$14.78263.23K

Latest DBVT news

The latest Smart Investors Daily articles mentioning DBVT.

DBVT research

Overview

Company profile and research snapshot.

Company profile

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$35.00
Implied upside
Analysts
DBVT recent ratings
DateFirmRatingTarget
Jun 17, 2024PORTZAMPARC BNP PARIBASBuy
Jun 16, 2024PORTZAMPARC BNP PARIBASBuy
Mar 14, 2024SOCIETE GENERALEBuy
Mar 13, 2024SOCIETE GENERALEBuy
Dec 19, 2023PORTZAMPARC BNP PARIBASBuy
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 DateTotal number of sharesTotal number of voting rights08/31/2026 314,388,807 Total gross of voting rights: 314,388,807 Total net* of voting rights: 314,222,095 * Net total = total number of voting rights attached to shares – shares without vo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.